These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34407991)

  • 1. Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450.
    Smith S; Lyman M; Ma B; Tweedie D; Menzel K
    Drug Metab Dispos; 2021 Nov; 49(11):995-1002. PubMed ID: 34407991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of Fraction Metabolized by Cytochrome P450 Enzymes Using Long-Term Cocultured Human Hepatocytes.
    Klammers F; Goetschi A; Ekiciler A; Walter I; Parrott N; Fowler S; Umehara K
    Drug Metab Dispos; 2022 May; 50(5):566-575. PubMed ID: 35246464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method.
    Yang X; Atkinson K; Di L
    Drug Metab Dispos; 2016 Mar; 44(3):460-5. PubMed ID: 26700955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes).
    Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP
    Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
    Chen Y; Liu L; Nguyen K; Fretland AJ
    Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.
    Khojasteh SC; Prabhu S; Kenny JR; Halladay JS; Lu AY
    Eur J Drug Metab Pharmacokinet; 2011 Mar; 36(1):1-16. PubMed ID: 21336516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
    Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes.
    Chanteux H; Rosa M; Delatour C; Nicolaï J; Gillent E; Dell'Aiera S; Ungell AL
    Drug Metab Dispos; 2020 Sep; 48(9):778-787. PubMed ID: 32532738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity.
    Kahma H; Aurinsalo L; Neuvonen M; Katajamäki J; Paludetto MN; Viinamäki J; Launiainen T; Filppula AM; Tornio A; Niemi M; Backman JT
    Eur J Pharm Sci; 2021 Jul; 162():105810. PubMed ID: 33753217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
    Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
    Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture.
    Chan TS; Scaringella YS; Raymond K; Taub ME
    Drug Metab Dispos; 2020 Aug; 48(8):690-697. PubMed ID: 32503882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous Screening of Activities of Five Cytochrome P450 and Four Uridine 5'-Diphospho-glucuronosyltransferase Enzymes in Human Liver Microsomes Using Cocktail Incubation and Liquid Chromatography-Tandem Mass Spectrometry.
    Lee B; Ji HK; Lee T; Liu KH
    Drug Metab Dispos; 2015 Jul; 43(7):1137-46. PubMed ID: 25904760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac.
    Chan TS; Yu H; Moore A; Khetani SR; Tweedie D
    Drug Metab Dispos; 2013 Dec; 41(12):2024-32. PubMed ID: 23959596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
    Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
    J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
    Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
    Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-
    Cuypers ML; Chanteux H; Gillent E; Bonnaillie P; Saunders K; Beckers C; Delatour C; Dell'Aiera S; Ungell AL; Nicolaï J
    Drug Metab Dispos; 2020 Nov; 48(11):1121-1128. PubMed ID: 32839278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and Inhibition.
    Gonzalez E; Jain S; Shah P; Torimoto-Katori N; Zakharov A; Nguyễn ÐT; Sakamuru S; Huang R; Xia M; Obach RS; Hop CECA; Simeonov A; Xu X
    Drug Metab Dispos; 2021 Sep; 49(9):822-832. PubMed ID: 34183376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Uttamsingh V; Lu C; Miwa G; Gan LS
    Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
    Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
    Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.